EMA Authorised: Filspari (sparsentan) — Vifor France

View source ↗

Summary

The European Medicines Agency has authorised Filspari (sparsentan) for glomerulonephritis, including IgA nephropathy, with orphan designation; the marketing aut…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glomerulonephritis
• Iga Nephropathy

Drugs mentioned

• FILSPARI (SPARSENTAN)

Snippet

Status: Authorised. Therapeutic area: Glomerulonephritis, IGA. MAH: Vifor France. Decision date: 13/11/2025. Orphan medicine